| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| PTC THERAPEUTICS, INC. | Director | Common Stock | 14.5K | $554K | $38.24 | May 22, 2024 | Direct |
| PTC THERAPEUTICS, INC. | Director | Stock Option (Right to Buy) | 0 | $0 | $27.05 | May 22, 2024 | Direct |
| NexImmune, Inc. | Executive VP of Research & Dev | Stock Option (Right to Buy) | 80.1K | Apr 5, 2022 | Direct | ||
| SOLIGENIX, INC. | Director | Stock Option (Right to Buy) | 38.1K | Dec 15, 2023 | Direct | ||
| NEXGEL, INC. | Director | Stock Option (Right to Buy) | 15K | Aug 17, 2023 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| PTCT | PTC THERAPEUTICS, INC. | May 22, 2024 | 3 | -$236K | 4 | May 24, 2024 | Director |
| PTCT | PTC THERAPEUTICS, INC. | Feb 15, 2024 | 2 | $0 | 4 | Feb 16, 2024 | Director |
| SNGX | SOLIGENIX, INC. | Dec 15, 2023 | 1 | $0 | 4 | Dec 15, 2023 | Director |
| NXGL | NEXGEL, INC. | Aug 17, 2023 | 1 | $0 | 4 | Aug 21, 2023 | Director |
| NXGL | NEXGEL, INC. | May 26, 2023 | 1 | $11.7K | 4 | May 30, 2023 | Director |
| PTCT | PTC THERAPEUTICS, INC. | Jan 5, 2023 | 2 | $0 | 4 | Jan 9, 2023 | Director |
| SNGX | SOLIGENIX, INC. | Nov 17, 2022 | 1 | $0 | 4 | Nov 21, 2022 | Director |
| NEXI | NexImmune, Inc. | Apr 5, 2022 | 1 | $0 | 4 | Apr 7, 2022 | Executive VP of Research & Dev |
| NXGL | NEXGEL, INC. | Mar 25, 2022 | 1 | $10K | 4 | Mar 28, 2022 | Director |
| PTCT | PTC THERAPEUTICS, INC. | Jan 7, 2022 | 2 | $0 | 4 | Jan 11, 2022 | Director |
| NXGL | NEXGEL, INC. | Dec 27, 2021 | 2 | $50K | 4 | Jan 3, 2022 | Director |
| SNGX | SOLIGENIX, INC. | Sep 23, 2021 | 1 | $0 | 4 | Sep 24, 2021 | Director |
| SNGX | SOLIGENIX, INC. | May 14, 2021 | 2 | -$37 | 4 | May 18, 2021 | Director |